Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Christina Antonopoulos

Retina Specialist Baltimore, MD Medical Doctor

NPI 1992820641 CMS profile 647729

2925 Lord Baltimore Dr, Suite 300, Baltimore, MD 21244

Open in the dashboard

General payments

$304

6 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Christina Antonopoulos of Baltimore, MD is reported in the CMS Open Payments database as having received $304 across 6 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 11th percentile of Retina Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $100 1
2022 General $83 1
2020 General $37 2
2019 General $84 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christina Antonopoulos
  • Retina Specialist median
  • Middle half of Retina Specialist
  • National median

In program year 2025, general payments to Christina Antonopoulos were reported at $0. Among 1,235 Retina Specialist profiles paid that year, the median was $457 and the middle half received between $175 and $1,079.

Show as a table
Year Christina Antonopoulos Retina Specialist median Middle half National median
2019 $84 $410 $157–$1,517 $163
2020 $37 $168 $65–$778 $114
2021 $0 $258 $101–$1,161 $132
2022 $83 $418 $162–$1,488 $149
2023 $0 $476 $178–$1,312 $160
2024 $100 $520 $188–$1,372 $164
2025 $0 $457 $175–$1,079 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Optos, Inc. $100 1 payment
  2. Bausch & Lomb, a division of Bausch Health US, LLC $84 2 payments
  3. Bausch & Lomb Americas Inc. $83 1 payment
  4. Carl Zeiss Meditec AG $19 1 payment
  5. Carl Zeiss Meditec, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $167 3 payments
  2. Entertainment $100 1 payment
  3. Gift $37 2 payments
Products named General payments · program years 2019–2024
  1. NFC-700 $100 1 payment
  2. OCT OPHTHALMOSCOPE Ophthalmology $100 1 payment
  3. PANORAMIC OPHTHALMOSCOPE Ophthalmology $100 1 payment
  4. PANORAMIC OPHTHALMOSCOPE Ophthalmology $100 1 payment
  5. OCT OPHTHALMOSCOPE Ophthalmology $100 1 payment
  6. enVista MX60 IOL $83 1 payment
  7. LOTEMAX SM $72 1 payment
  8. None Specified $37 2 payments
  9. VYZULTA $12 1 payment
  10. BESIVANCE $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

285

Median for Ophthalmology: 891

Drug cost

$6,580

Median for Ophthalmology: $68,233

Branded share of claims

21.1%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 52 $2,601
Latanoprost Generic 77 $1,380
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 60 $1,018
Ketorolac Tromethamine Generic 12 $634
Brimonidine Tartrate Generic 38 $334
Atropine Sulfate Generic 13 $243
Timolol Maleate Generic 19 $239
Ofloxacin Generic 14 $131

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$456,956

Of which drugs: $313,659

Medicare patients

470

Average age 77

Services billed

3,970

282 women, 188 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 38%
Ischemic heart disease 29%
Chronic kidney disease 20%
Depression 20%
Atrial fibrillation 17%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 Office 35 296 $193,971
Injection, bevacizumab, 10 mg J9035 Office 69 239 $12,556

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

6 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Retina Specialist in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record